Literature DB >> 34956926

Clinical Consequences of Variable Results in the Measurement of Free Thyroid Hormones: Unusual Presentation of a Family with a Novel Variant in the THRB Gene Causing Resistance to Thyroid Hormone Syndrome.

Irene Campi1, Maura Agostini2, Federica Marelli1, Tiziana de Filippis1, Beatriz Romartinez-Alonso3, Odelia Rajanayagam2, Giuditta Rurale1, Ilaria Gentile4, Federica Spagnolo5, Massimiliano Andreasi6, Francesco Ferraù5,7, Salvatore Cannavò5,7, Laura Fugazzola1,8, Krishna V Chatterjee2, Luca Persani1,4.   

Abstract

INTRODUCTION: Resistance to thyroid hormone β (RTHβ) is an inherited syndrome caused by dominant negative variants in the THRB gene (NM_000461.5). The clinical picture of RTHβ is variable, and patients harboring the same variant may display different degrees of disease severity. CASE
PRESENTATION: A 30-year-old man presented with thyrotoxicosis and central hyperthyroidism and was found to have a novel variant in the exon 10 of THRB gene (c.C1282G, p.L428V), located within the third hot spot region of the C-terminal of the receptor. Surprisingly, the same variant was found in two other relatives with an apparent normal thyroid function at initial screening. After exclusion of a TSH-secreting adenoma and serum interference in the proband, and the finding that exogenous levothyroxine failed to suppress the TSH in the brother affected by nodular goiter, relatives' thyroid function tests (TFTs) were reassessed with additional analytical method revealing biochemical features consistent with RTHβ in all carriers of the p.L428V variant. Functional studies showed a slightly impaired in vitro transcriptional activity of p.L428V. Interestingly' the expression of the human p.L428V thyroid hormone receptor beta in the zebrafish embryo background generated a phenotype consistent with RTHβ.
CONCLUSION: Variable results of TFTs on some immunoassays can be a cause of RTHβ diagnostic delay, but the genotype-phenotype correlation in this family and functional studies support p.L428V as a novel THRB variant expanding the spectrum of gene variants causing RTHβ. In vivo, rather than in vitro, functional assays may be required to demonstrate the dominant negative action of THRB variants.
Copyright © 2021 by European Thyroid Association. Published by S. Karger AG, Basel.

Entities:  

Keywords:  Anti-T4 antibodies; Central hyperthyroidism; Nodular goiter; RTHβ; THRB

Year:  2021        PMID: 34956926      PMCID: PMC8647126          DOI: 10.1159/000519748

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  26 in total

1.  Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories.

Authors:  Bernard W Steele; Edward Wang; George G Klee; Linda M Thienpont; Steven J Soldin; Lori J Sokoll; William E Winter; Susan A Fuhrman; Ronald J Elin
Journal:  Arch Pathol Lab Med       Date:  2005-03       Impact factor: 5.534

2.  Do clinical manifestations of resistance to thyroid hormone correlate with the functional alteration of the corresponding mutant thyroid hormone-beta receptors?

Authors:  Y Hayashi; R E Weiss; D H Sarne; P M Yen; T Sunthornthepvarakul; C Marcocci; W W Chin; S Refetoff
Journal:  J Clin Endocrinol Metab       Date:  1995-11       Impact factor: 5.958

Review 3.  Genetic determination of the hypothalamic-pituitary-thyroid axis: where do we stand?

Authors:  Marco Medici; W Edward Visser; Theo J Visser; Robin P Peeters
Journal:  Endocr Rev       Date:  2015-03-09       Impact factor: 19.871

4.  Apparent resistance to thyroid hormones: From biological interference to genetics.

Authors:  Xavier Dieu; Guillaume Sueur; Valérie Moal; Florence Boux de Casson; Nathalie Bouzamondo; Natacha Bouhours; Claire Briet; Frédéric Illouz; Pascal Reynier; Régis Coutant; Patrice Rodien; Delphine Mirebeau-Prunier
Journal:  Ann Endocrinol (Paris)       Date:  2019-07-26       Impact factor: 2.478

5.  Spectrum of transcriptional, dimerization, and dominant negative properties of twenty different mutant thyroid hormone beta-receptors in thyroid hormone resistance syndrome.

Authors:  T N Collingwood; M Adams; Y Tone; V K Chatterjee
Journal:  Mol Endocrinol       Date:  1994-09

6.  A Novel G385E Variant in the Cold Region of the T3-Binding Domain of Thyroid Hormone Receptor Beta Gene and Investigations to Assess Its Clinical Significance.

Authors:  Manassawee Korwutthikulrangsri; Chrysoula Dosiou; Alexandra M Dumitrescu; Samuel Refetoff
Journal:  Eur Thyroid J       Date:  2019-10-30

7.  Classification and proposed nomenclature for inherited defects of thyroid hormone action, cell transport, and metabolism.

Authors:  Samuel Refetoff; J H Duncan Bassett; Paolo Beck-Peccoz; Juan Bernal; Gregory Brent; Krishna Chatterjee; Leslie J De Groot; Alexandra M Dumitrescu; J Larry Jameson; Peter A Kopp; Yoshiharu Murata; Luca Persani; Jacques Samarut; Roy E Weiss; Graham R Williams; Paul M Yen
Journal:  Thyroid       Date:  2014-03-04       Impact factor: 6.568

8.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

9.  Avoiding Misdiagnosis Due to Antibody Interference with Serum Free Thyroxin.

Authors:  Pilar I Beato-Víbora; S Alejo-González
Journal:  Int J Endocrinol Metab       Date:  2016-11-14

10.  A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia.

Authors:  Nadia Schoenmakers; Carla Moran; Irene Campi; Maura Agostini; Olivia Bacon; Odelia Rajanayagam; John Schwabe; Sonia Bradbury; Timothy Barrett; Frank Geoghegan; Maralyn Druce; Paolo Beck-Peccoz; Angela O'Toole; Penelope Clark; Michelle Bignell; Greta Lyons; David Halsall; Mark Gurnell; Krishna Chatterjee
Journal:  J Clin Endocrinol Metab       Date:  2014-03-19       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.